Try it
General Medicine · Infectious diseases: COVID-19 steroid use
Sample itemA patient with COVID-19 has SpO2 of 88 percent on room air requiring supplemental oxygen. Which drug has shown a mortality benefit in this group?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
D. Dexamethasone
In patients with COVID-19 who need oxygen or ventilation, dexamethasone 6 mg daily for up to 10 days reduces mortality in the RECOVERY trial. It is not beneficial in those without oxygen requirement. Hydroxychloroquine, ivermectin and azithromycin have not shown mortality benefit.
Option by option
A. Hydroxychloroquine
Hydroxychloroquine did not improve outcomes.
B. Ivermectin
Ivermectin lacks proven benefit.
C. Azithromycin
Azithromycin is not beneficial for viral illness.
D. Dexamethasone (correct)
Correct. Dexamethasone reduces mortality in hypoxaemic patients.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More General Medicine questions
- EndocrinologyA 19-year-old with type 1 diabetes presents with vomiting, deep rapid breathing, fruity…
- ElectrolytesWhich is the earliest ECG change in hyperkalaemia?
- Infectious diseaseWhat is the drug of choice for Pneumocystis jirovecii pneumonia in a patient with advanc…
- NeurologyA chronic alcohol user is brought in confused, with nystagmus and an unsteady gait. What…